Finished product reference
Lutetium (177lu) Ethylenediamine Tetramethylene Phosphate (177lu-edtmp)
Injection, Solution · Parenteral · 200 mCi
- List code
- 52648
- Pharmacologic class
- Radiopharmaceutical: lutetium-177 EDTMP (bone-seeking agent)
What it is and how it works
Lutetium-177 ethylenediamine tetramethylene phosphonate is a phosphonate complex that localises in areas of increased osteoblastic activity in bone. Beta emission from lutetium-177 irradiates skeletal metastases and relieves bone pain, while its gamma emission allows imaging of distribution.
Indications
Palliation of pain from osteoblastic or mixed skeletal metastases (e.g. prostate and breast cancer) confirmed by bone scintigraphy.
Dosage and administration (summary)
Administered by slow intravenous injection in a nuclear medicine facility; activity is individualised according to protocol and body weight.
Contraindications
Pregnancy and breast-feeding; significant pre-existing bone-marrow suppression; hypersensitivity.
Warnings and precautions
Transient myelosuppression (thrombocytopenia and leucopenia) may occur; monitor blood counts for several weeks. A temporary increase in bone pain (flare) can occur after injection. Ensure adequate hydration and frequent voiding to reduce bladder radiation dose; radiation-protection precautions are required.
Pregnancy
Contraindicated in pregnancy.
Storage and supply
Store in lead shielding according to the manufacturer’s instructions and radiation-protection regulations; short shelf life due to radioactive decay.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.